ESTRO meets Asia 2024 - Abstract Book

S44

Invited Speaker

ESTRO meets Asia 2024

5 study. On the other hand, patients with unresectable EGFR-mutant stage III NSCLC can now be treated with radical concurrent chemoradiation followed by osimertinib. Ongoing trials shall bring new insights and solutions to the management of locally advanced NSCLC showing a diversity of clinical and genomic presentation.

This lecture shall provide an overview and latest advances on multidisciplinary management of locally advanced NSCLC.